Zai Lab Partner, GSK, Announces U.S. Food and Drug Administration Approval of Additional Indication for Zejula (niraparib) for Late-line Treatment for Women with Recurrent Ovarian Cancer

Matthew Durham
Omnidynamic Marketing

Suma Ramadas, PhD
Medical Affairs

Brenda Snow
Authentic Patient Voice

Liz Kane
Impactful Strategy

Joey Cohen
Medication Adherence

Paul Theisen
Patient Acquisition

Frank Burrell
Scientific Storytelling

David Linetsky
Point-of-Care Marketing

Stacey Gandler
Brand Nourishment

Daniel Sontupe
Market Access

Matt Turner
Patient Affordability

Amy Giles
Increasing Engagement

Pat Purcell
Meeting Engagement

Bud Bilanich
Success Coach